Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 106.00

+0.8%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	2/28/2014 7:52:21 AM
	Read Replies (1) of 3202

On the INCY competition front... "Galapagos NV ( GLPGF) announced today that GSK has updated the development status for GSK2586184, involving three clinical studies in psoriasis, lupus, and ulcerative colitis." Now the meat... "All dosing of patients in the Phase 2 study in psoriasis has completed. Topline efficacy and safety results from this study are expected in the first half of 2014. Galapagos is eligible to receive a milestone payment from GSK in the event that GSK achieves a successful Proof-of-Concept in patients treated with GSK2586184. The psoriasis study was designed to recruit 64 patients, with treatment up to 12 weeks. The Phase 2 study in systemic lupus erythematosis has been stopped at the planned first interim analysis by GSK due to a lack of effect. GSK notified Galapagos that the pre-defined stopping criteria were clearly met, triggering GSK to discontinue the lupus study with GSK2586184. GSK has put the exploratory Phase 1/2 study in ulcerative colitis on hold. This study is designed to recruit up to 15 ulcerative colitis patients on treatment with GSK2586184." finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next